Aadi Bioscience Q1 2022: FYARRO sales $2.3M; net loss $13.9M; first patient dosed in PRECISION 1 trial

Whitehawk Therapeutics, Inc.

2023-Q1 EPS reported -$0.66 revenue$2,307,000

Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.
Net loss for Q1 2022 was $13.9M vs $5.5M in Q1 2021; operating expenses $16.1M vs $4.2M.
Cash and equivalents $129.8M as of Mar 31, 2022, expected to fund operations into 2024.
First patient dosed in PRECISION 1 Phase 2 tumor-agnostic trial for TSC1/TSC2 altered tumors; initial data expected H1 2023.
Permanent J-code (J9331) for FYARRO granted, effective Jul 1, 2022; partnerships with Foundation Medicine and Tempus for trial enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.